Minerva endocrinology最新文献

{"title":"Managing intracranial tumors during gender-affirming hormone therapy.","authors":"Arianna Barbotti, Adriana Godano, Francesco Dimeco, Alessandro Perin","doi":"10.23736/S2724-6507.24.04241-6","DOIUrl":"10.23736/S2724-6507.24.04241-6","url":null,"abstract":"","PeriodicalId":18690,"journal":{"name":"Minerva endocrinology","volume":" ","pages":"354-356"},"PeriodicalIF":1.9,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141734640","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Highlights of the July-September 2025 issue.","authors":"Giovanni Vitale","doi":"10.23736/S2724-6507.25.04433-1","DOIUrl":"https://doi.org/10.23736/S2724-6507.25.04433-1","url":null,"abstract":"","PeriodicalId":18690,"journal":{"name":"Minerva endocrinology","volume":"50 3","pages":"245-247"},"PeriodicalIF":1.9,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145233002","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cancer cell xenografts in zebrafish embryos as an experimental tool in drug screening for adrenocortical carcinoma.","authors":"Mariangela Tamburello, Andrea Abate, Sandra Sigala","doi":"10.23736/S2724-6507.24.04270-2","DOIUrl":"10.23736/S2724-6507.24.04270-2","url":null,"abstract":"<p><p>Despite the widespread use of murine models in in-vivo experiments, the zebrafish (Danio rerio) offers unique advantages that make it a versatile and faster preclinical model for drug screening, particularly for adrenocortical carcinoma (ACC), a rare malignancy with limited preclinical models that reflect patient heterogeneities. Over the past decade, significant progress has been made with models like cell lines, organoids, and murine models, which are crucial for advancing disease understanding and treatment development. However, recent reviews have overlooked zebrafish model for ACC. This mini review aims to fill this gap by detailing the advancements of the zebrafish model in ACC research. Recent studies have utilized zebrafish embryos xenografted with ACC cells as a novel approach to studying drug effects on tumor growth and metastasis, consistent with studies regarding other tumors. Specifically, it was demonstrated the ability of abiraterone acetate, trabectedin and progesterone to significantly reduce the tumor area at non-toxic-concentrations. Interestingly, this model allowed to confirm in vivo that metastasis-derived cells were able to metastasize and that trabectedin and progesterone reduced the rate of embryos with metastasis. One more study showed that metastasis formation was significantly reduced in H295R/TR-SF-1-xenografted embryos after fascin1 knock-out or inhibition with G2-044. Even with some limitations, the zebrafish xenografts offer a suitable and expeditious animal model for the screening of potentially effective drugs, identification of dose toxicity, and determination of the most promising compounds for more advanced preclinical phases, especially in rare diseases with limited therapeutic options such as ACC.</p>","PeriodicalId":18690,"journal":{"name":"Minerva endocrinology","volume":" ","pages":"182-193"},"PeriodicalIF":2.5,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143492888","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Telemedicine for type 2 diabetes during COVID-19 pandemic: experience from a tertiary diabetes center.","authors":"Silvia Angelino, Paola Caruso, Miriam Longo, Mariluce Barrasso, Filomena Castaldo, Alessandro Pontillo, Stefania Arena, Annarita Palmieri, Giuseppe Bellastella, Maria I Maiorino, Katherine Esposito","doi":"10.23736/S2724-6507.23.04096-4","DOIUrl":"10.23736/S2724-6507.23.04096-4","url":null,"abstract":"<p><strong>Background: </strong>Telemedicine was largely employed during COVID-19 pandemic to guarantee continuity of care in a period of dramatic reduction of face-to-face visits. The aim of this study was to describe the clinical characteristics of a cohort of patients with type 2 diabetes followed by tele-visits and to evaluate the changes in the glyco-metabolic control during a 12-month follow-up.</p><p><strong>Methods: </strong>This retrospective observational study included 136 adults aged >18 years with at least three tele-visits over a 12-month follow-up period, in a Diabetes Center of the Southern Italy, from April 2020 to March 2022. Data related to glycemic and lipid profile, therapy, presence of micro or macrovascular complications, and other clinical features were extracted at three time points, at first visit (T0), after 6 months (T1) and after 12 months (T2).</p><p><strong>Results: </strong>Mean diabetes duration and median HbA1c values were 11.6 years and 7.0%, respectively. Thirty-eight participants (27.9%) presented macro- or microvascular complications. Glycemic control remained stable over time, without clinically significant changes of HbA<inf>1c</inf> (T0 vs. T1 vs. T2, median [IQR], 7.0 [6.2-7.3], 6.6 [6.0-7.5], 6.9 [6.2-7.5], P=0.095) and fasting glucose. Lipid profile slightly improved, although without significant clinical change. Glucose lowering therapy was modified in 84 patients (61.8%) and remained unchanged in 52 patients (38.2%) during the follow-up. No participant in the study developed any complications during the 12-month follow-up.</p><p><strong>Conclusions: </strong>People with type 2 diabetes followed by telemedicine were adults with fair glucose control generally free from chronic complications, whose diabetes control did not worsen during a 12-month follow-up.</p>","PeriodicalId":18690,"journal":{"name":"Minerva endocrinology","volume":" ","pages":"163-171"},"PeriodicalIF":2.5,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139575467","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Insulin resistance is associated with increased circulating lipocalin-2 levels in polycystic ovary syndrome: a systematic review and meta-analysis.","authors":"Seshadri R Varikasuvu, Faustino R Pérez-López, Anirban Ganguly, Subodh Kumar, Anandakumar Pandi, Jitender Prasad, Vanita Lal DAS","doi":"10.23736/S2724-6507.22.03926-4","DOIUrl":"10.23736/S2724-6507.22.03926-4","url":null,"abstract":"<p><strong>Introduction: </strong>This meta-analysis was conducted to compare the circulating lipocalin-2 levels in polycystic ovary syndrome (PCOS).</p><p><strong>Evidence acquisition: </strong>Relevant studies were retrieved by online database and manual searching. The standardized mean differences (SMDs) with 95% confidence intervals (CIs) were obtained by a random-effects meta-analysis. The subgroup analysis based on the Body Mass Index (BMI) and the homeostasis model assessment-estimated insulin resistance (HOMA-IR) was conducted. Meta-analysis of correlations and meta-regression were performed for the associations of lipocalin-2 with the metabolic and hormonal covariates. The funnel plot analysis was used for publication bias.</p><p><strong>Evidence synthesis: </strong>The combined effect size including a total of 13 studies showed no significant difference in lipocalin-2 levels between PCOS and control groups. However, the subgroup meta-analysis based on insulin resistance showed a significant difference in the circulatory lipocalin-2 levels in PCOS as compared to controls in both HOMA-IR<3 (SMD=-1.15, Z=2.42, P=0.02) and HOMA-IR>3 subgroups (SMD=0.91, Z=2.43, P=0.02).</p><p><strong>Conclusions: </strong>There were significant associations of lipocalin-2 with age, BMI, estrogen and hyperandrogenism in PCOS. Lipocalin-2 level alterations in PCOS are associated to insulin resistance. More is the insulin resistance, higher is the lipocalin-2 level in PCOS as compared to controls.</p>","PeriodicalId":18690,"journal":{"name":"Minerva endocrinology","volume":" ","pages":"194-200"},"PeriodicalIF":2.5,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10531079","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Endocrinologist's crucial role in metabolic dysfunction-associated steatotic liver disease: a comprehensive review.","authors":"Claudia Reytor-González, Giuseppe Annunziata, Martín Campuzano-Donoso, Tania Morales-López, Carmen Basantes-Tituaña, Federica Fascì-Spurio, Ludovica Verde, Giovanna Muscogiuri, Luigi Barrea, Evelyn Frias-Toral, Daniel Simancas-Racines","doi":"10.23736/S2724-6507.24.04314-8","DOIUrl":"10.23736/S2724-6507.24.04314-8","url":null,"abstract":"<p><p>Metabolic dysfunction-associated steatotic liver disease (MASLD) is a widespread disorder strongly associated with metabolic conditions such as obesity, insulin resistance, and type 2 diabetes (T2D). The progression of MASLD, which can lead to severe complications like hepatic fibrosis and cirrhosis, is closely tied to cardiometabolic risks, including cardiovascular disease, and to liver-related cancers associated with metabolic dysfunction. Endocrinologists are uniquely positioned to detect MASLD early, particularly in individuals with metabolic risk factors such as T2D, polycystic ovary syndrome (PCOS), and thyroid dysfunction. While they may not routinely perform advanced diagnostic procedures, they play a critical role in identifying at-risk patients and collaborating with specialists for further evaluation, including the use of transient elastography to assess liver stiffness and fibrosis. By doing so, they help reduce the need for invasive procedures. Beyond screening and diagnosis, endocrinologists collaborate with hepatologists, cardiologists, and nutritionists to ensure a comprehensive, multidisciplinary treatment approach. Managing MASLD requires addressing both liver-specific conditions and broader metabolic dysfunctions through lifestyle interventions and pharmacological therapies. Recent studies highlight the potential benefits of medications, such as farnesoid X receptor (FXR) agonists and peroxisome proliferator-activated receptor (PPAR) agonists, when combined with lifestyle interventions such as modifying diet and engaging in more physical activity. This review highlights the pivotal role of endocrinologists in managing MASLD, focusing on their contributions to screening, diagnosis, and integrated care. It examines the complex interplay between hormonal regulation and both pharmacological and non-non-pharmacological treatment strategies, providing insights for enhancing clinical practice and improving patient outcomes through a comprehensive, multidisciplinary approach.</p>","PeriodicalId":18690,"journal":{"name":"Minerva endocrinology","volume":" ","pages":"209-226"},"PeriodicalIF":2.5,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143674390","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Highlights of the April-June 2025 issue.","authors":"Giovanni Vitale","doi":"10.23736/S2724-6507.25.04394-5","DOIUrl":"10.23736/S2724-6507.25.04394-5","url":null,"abstract":"","PeriodicalId":18690,"journal":{"name":"Minerva endocrinology","volume":"50 2","pages":"123-125"},"PeriodicalIF":2.5,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144369070","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Association between circulating betatrophin levels and T2DM: a meta-analysis.","authors":"Yuquan Zhan","doi":"10.23736/S2724-6507.23.04073-3","DOIUrl":"10.23736/S2724-6507.23.04073-3","url":null,"abstract":"<p><strong>Introduction: </strong>The association between betatrophin level and type 2 diabetes mellitus (T2DM) is a subject of controversy, and the reasons for conflicting results have been poorly explained. To address this gap, we conducted a meta-analysis of relevant studies to obtain a more comprehensive estimate and draw a more accurate conclusion.</p><p><strong>Evidence acquisition: </strong>This study included literature published up to June 2023. We searched for relevant studies in the Web of Science and PubMed databases. We utilized STATA 12.0 software to calculate the standard mean difference (SMD) and 95% confidence interval (CI) to compare circulating betatrophin levels between individuals with T2DM and healthy controls (HCs).</p><p><strong>Evidence synthesis: </strong>The meta-analysis revealed a significantly higher circulating betatrophin level in individuals with T2DM compared to HC, using a random effects model [mean value of betatrophin level (T2DM vs. HC): 388,685.23 vs. 304,857.04 pg/mL; SMD=1.37; 95%CI: 1.01, 1.73]. Subgroup analysis indicated a higher circulating betatrophin level in T2DM compared to HC among Asian individuals, while no significant difference in circulating betatrophin level was observed between T2DM and HC among Caucasian individuals (Asian: SMD=1.65; 95%CI: 1.23, 2.06; Caucasian: SMD=0.50; 95%CI: -0.21, 1.20). Additionally, subgroup analysis revealed increased plasma and serum betatrophin levels in T2DM compared to HC (plasma: SMD=1.30; 95%CI: 0.72, 1.88; serum: SMD=1.47; 95%CI: 0.98, 1.96).</p><p><strong>Conclusions: </strong>This meta-analysis provides evidence of elevated levels of betatrophin in individuals with T2DM, suggesting that betatrophin may serve as a potential diagnostic biomarker for T2DM.</p>","PeriodicalId":18690,"journal":{"name":"Minerva endocrinology","volume":" ","pages":"201-208"},"PeriodicalIF":2.5,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139472752","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The severity of menopausal symptoms is associated with diabetes, and cardiometabolic risk factors in middle-aged women.","authors":"Eleni Armeni, Stylianos Kopanos, Eleni Verykouki, Areti Augoulea, Stavroula A Paschou, Demetrios Rizos, George Kaparos, Makarios Eleftheriadis, Anna-Bettina Haidich, Dimitrios G Goulis, Nikolaos Vlahos, Irene Lambrinoudaki","doi":"10.23736/S2724-6507.23.03905-2","DOIUrl":"10.23736/S2724-6507.23.03905-2","url":null,"abstract":"<p><strong>Background: </strong>Ovarian senescence is associated with increased cardiovascular risk. We aimed to evaluate the association between menopausal symptoms and cardiometabolic risk factors in a cohort of apparently healthy middle-aged women.</p><p><strong>Methods: </strong>The cohort included 2793 peri- and postmenopausal women not on menopausal hormone therapy. Demographic/anthropometric and biochemical/hormonal data were assessed. The severity of menopausal symptoms was evaluated by the Greene Climacteric Scale (GCS).</p><p><strong>Results: </strong>GCS-Total Score was associated with BMI (b=0.12, 95% CI: 0.04 to 0.20), T2DM (b=2.10, 95% CI: 0.06 to 4.15), and late-postmenopause (b=-1.24, 95% CI: -2.17 to -0.33). GCS-psychological score was associated with BMI (b=0.06, 95% CI: 0.00 to 0.11). GCS-Physical Score was associated with BMI (b=0.06, 95% CI: 0.03 to 0.09), central obesity (b=0.18, 95% CI: 0.02 to 0.34), and postmenopause (early-/late-postmenopause vs. perimenopause, b=-0.36, 95% CI: -0.59 to -0.13 and b=-0.65, 95% CI: -0.97 to -0.34, respectively). All GCS-scores were negatively associated with age. GCS-Sexual Score was associated with early-postmenopause (incidence rate ratio (IRR)=1.53, 95% CI: 1.21 to 1.94), central obesity (IRR=1.18, 95% CI: 1.00 to 1.39), smoking, diastolic blood pressure, age. Cox-regression analysis showed that incident T2DM was positively associated with increasing age, BMI, daily alcohol consumption, moderate-to-severe vasomotor symptoms (VMS, OR=1.045, 95% CI: 1.011 to 1.079), and negatively with moderate-to-strenuous physical activity. These associations persisted in lean but not in obese women.</p><p><strong>Conclusions: </strong>The severity of menopausal symptoms is associated with T2DM, obesity, and smoking in a cohort of peri-/postmenopausal women. VMS were associated with incident T2DM, especially in lean women. These associations must be considered in implementing primary and secondary prevention strategies.</p>","PeriodicalId":18690,"journal":{"name":"Minerva endocrinology","volume":" ","pages":"151-162"},"PeriodicalIF":2.5,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10163322","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Associations of cerebrospinal fluid pressure and ocular anatomic parameters with diabetes and diabetic retinopathy.","authors":"Galina Dimitrova, Ivana Petkovska, Dushan Kemera, Natasha Nedeska Minova, Hasan Taner, Antonela Ljubic, Lidija Lazareska, Etsuo Chihara","doi":"10.23736/S2724-6507.23.04078-2","DOIUrl":"10.23736/S2724-6507.23.04078-2","url":null,"abstract":"","PeriodicalId":18690,"journal":{"name":"Minerva endocrinology","volume":"50 2","pages":"241-243"},"PeriodicalIF":2.5,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144369069","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}